Evidence map›Paper›PMID 40421153›Full record

ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2025

Breast cancer screening for transgender individuals with breast cancer susceptibility genes.

Kamelah Abushalha, Andrew Ng, Soumya Pulipati, Prarthna V Bhardwaj

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kamelah AbushalhaDivision of Hematology-Oncology, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA.
Andrew NgDepartment of Internal Medicine, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA.
Soumya PulipatiDivision of Hematology-Oncology, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA.
Prarthna V BhardwajDivision of Hematology-Oncology, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transgender individuals represent a growing and very heterogeneous population, yet there are no precise estimates of their breast cancer risk and equitable breast cancer screening guidelines. They have lower rates of healthcare utilization and face disproportionate discrimination in comparison to cisgender individuals. Unfortunately, most national databases continue to report binary gender. Gender affirming hormone therapy (GAHT), surgical history, and psychosocial factors may complicate risk stratification and breast cancer screening decisions. Those with genetic predisposition to cancer, specifically breast cancer susceptibility genes like

Indexed as

BRCA1BRCA2breast cancerbreast cancer susceptibility genesTransgender

Identifiers

PMID40421153
PMCPMC12104954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.